Key Finding
Acupuncture and moxibustion significantly improved quality of life, reduced chemotherapy-induced nausea and vomiting by 68%, and enhanced immune function markers in non-small cell lung cancer patients undergoing standard treatment.
Researchers analyzed 39 studies involving 3,610 patients with non-small cell lung cancer (NSCLC) to determine whether acupuncture and moxibustion could help manage treatment side effects. NSCLC accounts for about 80-85% of all lung cancers, and while chemotherapy and surgery are essential treatments, they often cause difficult side effects like nausea, vomiting, and weakened immune function that significantly reduce quality of life.
The study examined whether adding acupuncture and moxibustion to standard cancer care could improve patients' overall wellbeing, reduce chemotherapy-induced nausea and vomiting, and support immune system function. Researchers searched nine major medical databases for high-quality randomized controlled trials comparing patients who received acupuncture or moxibustion alongside standard treatment versus those who received standard treatment alone.
The results showed significant benefits across multiple areas. Patients receiving acupuncture and moxibustion reported substantially better quality of life scores and improved physical functioning. These therapies reduced the occurrence of chemotherapy-induced nausea and vomiting by 68% and provided better symptom relief overall. Importantly, immune system markers improved, including increases in important immune cells (CD3, CD4) and a healthier balance of immune function, while inflammatory markers decreased.
For lung cancer patients undergoing chemotherapy, these findings suggest that acupuncture and moxibustion may be valuable complementary therapies. They appear to help manage some of the most challenging aspects of cancer treatment—reducing nausea and vomiting, supporting immune function, and improving overall quality of life—without interfering with standard medical care. If you're considering acupuncture or moxibustion as part of your cancer care, consult with a licensed acupuncturist experienced in oncology support.
This systematic review and meta-analysis examined 39 RCTs (N=3,610) evaluating acupuncture and moxibustion as adjunctive therapies for NSCLC patients undergoing standard treatment. Searches across nine databases identified trials measuring quality of life (QLQ-C30, KPS), chemotherapy-induced nausea and vomiting (CINV), and immune markers. Results demonstrated statistically significant improvements in QoL measures (QLQ-C30 MD=12.39, KPS MD=8.22; both P<.00001) and a 68% reduction in CINV incidence (RR=0.32, P<.00001). Immune function markers showed favorable modulation: CD3 (MD=7.20, P=.0002), CD4 (MD=4.89, P=.0003), CD4/CD8 ratio (MD=0.22, P<.00001), and decreased TNF-α (MD=-11.05, P=.04). Symptom relief improved significantly (RR=1.16, P<.00001). Clinical takeaway: Acupuncture and moxibustion demonstrate robust evidence as complementary interventions for managing treatment-related adverse effects and supporting immune function in NSCLC patients, warranting integration into integrative oncology protocols.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Acupuncture significantly improved total sleep time by approximately 30 minutes and sleep efficiency by 4.56% compared to control groups in breast cancer patients with systemic therapy-associated insomnia.
📌 Cognitive behavioral therapy and hypnosis have the strongest evidence for reducing vasomotor symptoms in breast cancer survivors, while acupuncture may provide modest benefit as an adjunctive nonpharmacological treatment option.
📌 Traditional acupuncture reduced hot flash and night sweat frequency by nearly 50% in breast cancer survivors taking tamoxifen, with sustained effects lasting at least 18 weeks after treatment ended.